Fc Receptor (FcR) and Antibody Effector Function in HIV Vaccine Discovery (R01) | PA 17 113

Frequently Asked Questions (FAQs)

What is the name of this NIH funding opportunity?

The funding opportunity is titled "Fc Receptor (FcR) and Antibody Effector Function in HIV Vaccine Discovery (R01)."

What is the Funding Opportunity Number (FON)?

The Funding Opportunity Number listed is PA 17 113.

What is the main goal of this opportunity?

The main goal is to support research that clarifies how antibodies generated by HIV vaccines help prevent infection, with a specific focus on antibody functions that depend on Fc receptor (FcR) interactions. The broader intent is to produce actionable knowledge that can help refine, prioritize, and advance HIV vaccine candidates that show protective promise by leveraging Fc-dependent antibody effector pathways.

What type of research is prioritized in this FOA?

This FOA prioritizes studies that move beyond classic neutralizing activity and instead examine how vaccine-elicited antibodies may reduce viral acquisition risk through FcR-mediated effector mechanisms. It also prioritizes work that identifies patterns of FcR engagement that correlate with protection in the context of vaccine-induced immune responses.

Does this opportunity focus only on neutralizing antibodies?

No. A central theme is that antibodies may contribute to protection in ways that extend beyond directly neutralizing the virus. The FOA emphasizes Fc-dependent functions that can be triggered when the antibody Fc portion engages Fc receptors on immune cells.

What are Fc receptors (FcRs) in the context of this FOA?

In the context described, Fc receptors are receptors expressed on immune cells that can bind the Fc portion of antibodies. This binding can trigger downstream effector functions that may help control or eliminate virus during very early stages of exposure.

Which immune cells are specifically mentioned as expressing Fc receptors?

The FOA mentions natural killer cells, macrophages, monocytes, dendritic cells, and neutrophils as examples of immune cells that express Fc receptors.

What kinds of mechanisms are applicants encouraged to study?

Applicants are encouraged to probe the mechanisms by which Fc-dependent antibody activities work in vivo and in relevant experimental systems, and to map functional profiles of FcR engagement associated with protective vaccination.

What does "FcR-mediated effector mechanisms" mean here?

Based on the description provided, it refers to antibody-driven functions that depend on Fc receptor engagement on immune cells, leading to downstream immune activities that may help block or control infection early after exposure.

What kinds of research questions does the FOA suggest investigators might address?

Examples suggested by the description include: identifying which Fc-mediated functions are most strongly linked to reduced acquisition risk; defining which antibody features drive beneficial FcR interactions; determining how vaccine regimens shape functional antibody qualities; and mapping FcR engagement signatures associated with protection.

What antibody features are specifically called out as relevant to beneficial FcR interactions?

The FOA description specifically mentions isotype/subclass, Fc glycosylation patterns, epitope specificity, and affinity as antibody features that may influence FcR interactions.

How is this FOA intended to support HIV vaccine development decisions?

It emphasizes translating immunologic insights into better vaccine development decisions by establishing FcR engagement signatures or antibody effector function patterns associated with protection. These findings can serve as benchmarks and evaluation tools for next-generation vaccine candidates.

What kinds of vaccine development choices could this research inform?

The description indicates the research could inform immunogen design, adjuvant selection, dosing strategies, and regimen comparisons, based on whether candidates reliably induce Fc-dependent responses similar to those seen in protective settings.

What grant mechanism is used for this opportunity?

This opportunity uses the NIH R01 grant mechanism.

What does the R01 mechanism imply about the type of project NIH expects?

Based on the provided information, the R01 mechanism is intended for well-developed research projects led by investigators, at a scale appropriate for substantial, multi-year studies with defined aims, rigorous methods, and strong justification for significance and innovation in HIV vaccine research.

What is the funding category for this opportunity?

The program is described as falling under the NIH health research funding category.

What CFDA numbers are associated with this funding opportunity?

The CFDA numbers listed are 93.855 and 93.856.

Is this funding described as discretionary or mandatory?

The opportunity is listed as discretionary funding.

Does the provided information specify an award ceiling?

No. The provided source data does not specify an award ceiling.

Does the provided information specify the expected number of awards?

No. The provided source data does not specify the expected number of awards.

Who is eligible to apply?

Eligibility is broad and includes many types of domestic U.S. organizations and certain international entities. The description lists eligible applicants such as state, county, and city or township governments; special district governments; independent school districts; public and state-controlled institutions of higher education; private institutions of higher education; federally recognized Native American tribal governments; tribal organizations that are not federally recognized; public housing authorities/Indian housing authorities; nonprofits with or without 501(c)(3) status (outside of higher education institutions); for-profit organizations other than small businesses; and small businesses.

Are foreign (non-U.S.) organizations eligible to apply?

Yes. The FOA explicitly includes non-domestic (non-U.S.) entities (foreign organizations) among eligible applicants.

Are U.S. territories or possessions eligible to apply?

Yes. The FOA explicitly mentions U.S. territories or possessions as eligible applicants.

Are faith-based or community-based organizations eligible to apply?

Yes. The FOA explicitly highlights faith-based or community-based organizations among additional eligible applicants.

Are minority-serving institutions explicitly encouraged or included in eligibility?

Yes. The FOA explicitly highlights multiple categories, including Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISIs); Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); and Tribally Controlled Colleges and Universities (TCCUs).

Are tribal entities eligible?

Yes. Eligible applicants include federally recognized Native American tribal governments and tribal organizations that are not federally recognized.

Are for-profit entities eligible?

Yes. The eligibility list includes for-profit organizations other than small businesses, and also includes small businesses.

Are eligible federal agencies included?

Yes. The FOA explicitly highlights eligible federal agencies as additional eligible applicants.

When was this opportunity created?

The source data indicates the opportunity was created on 2017-01-09.

What is the original closing date listed for this opportunity?

The source data lists an original closing date of 2020-01-07.

What is the core scientific emphasis of the announcement?

The core emphasis is on Fc receptor biology and antibody effector function as they relate to HIV vaccine discovery, with the intent of catalyzing collaborative, mechanistic research that can directly inform vaccine candidate selection and optimization.

Does the FOA encourage collaborative projects?

Yes. It describes NIH as encouraging investigator-driven, collaborative projects that examine Fc-dependent activities in vivo and in relevant experimental systems and that define FcR engagement profiles linked to protection.

What does "functional profiles" or "signatures" of FcR engagement refer to in this FOA?

In the provided description, this refers to patterns of how vaccine-elicited antibodies engage Fc receptors and the associated effector functions, where certain patterns may correlate with protective outcomes and could be used as benchmarks to evaluate vaccine candidates.